Editing List of antibody drugs

This list includes [[Approved_drug|approved]] and [[Investigational_drug|investigational drugs]] as well as drugs that have been withdrawn from market; consequently, the column ''Use'' does not necessarily indicate clinical usage. See the list of FDA approved therapeutic monoclonal antibodies in the [[Monoclonal_antibody_therapy|Monoclonal antibody therapy]] page.

[https://en.wikipedia.org/wiki/List_of_therapeutic_monoclonal_antibodies https://en.wikipedia.org/wiki/List_of_therapeutic_monoclonal_antibodies]

{| class="sortable wikitable"
|-
! Name
! Trade name
! Type
! Source
! Target
! Use
|-
| [[3F8|3F8]]
| 
| mab
| mouse
| [[GM2_(ganglioside)|GD2 ganglioside]]
| [[Neuroblastoma|neuroblastoma]]
|-
| [[8H9|8H9]]
| 
| mab
| mouse
| [[B7-H3|B7-H3]]
| neuroblastoma, sarcoma, metastatic brain cancers
|-
| [[Abagovomab|Abagovomab]]
| 
| mab
| mouse
| [[CA-125|CA-125]] (imitation)
| [[Ovarian_cancer|ovarian cancer]]
|-
| [[Abciximab|Abciximab]]
| ReoPro
| Fab
| chimeric
| [[CD41|CD41]] (integrin alpha-IIb)
| [[Platelet_aggregation_inhibitor|platelet aggregation inhibitor]]
|-
| [[Abituzumab|Abituzumab]]
| 
| mab
| humanized
| [[CD51|CD51]]
| cancer
|-
| [[Abrilumab|Abrilumab]]
| 
| mab
| human
| integrin α4β7
| [[Inflammatory_bowel_disease|inflammatory bowel disease]], [[Ulcerative_colitis|ulcerative colitis]], [[Crohn's_disease|Crohn's disease]]
|-
| [[Actoxumab|Actoxumab]]
| 
| mab
| human
| ''[[Clostridium_difficile_(bacteria)|Clostridium difficile]]''
| [[Clostridium_difficile_colitis|''Clostridium difficile'' colitis]]
|-
| [[Adalimumab|Adalimumab]]
| Humira
| mab
| human
| [[TNF-α|TNF-α]]
| [[Rheumatoid_arthritis|Rheumatoid arthritis]], [[Crohn's_Disease|Crohn's Disease]], Plaque [[Psoriasis|Psoriasis]], [[Psoriatic_Arthritis|Psoriatic Arthritis]], [[Ankylosing_Spondylitis|Ankylosing Spondylitis]], [[Juvenile_Idiopathic_Arthritis|Juvenile Idiopathic Arthritis]], [[Hemolytic_disease_of_the_newborn|Hemolytic disease of the newborn]]
|-
| [[Adecatumumab|Adecatumumab]]
| 
| mab
| human
| [[EpCAM|EpCAM]]
| [[Prostate_cancer|prostate]] and [[Breast_cancer|breast cancer]]
|-
| [[Aducanumab|Aducanumab]]
| 
| mab
| human
| [[Beta-amyloid|beta-amyloid]]
| Alzheimer's disease
|-
| [[Afasevikumab|Afasevikumab]]
| 
| mab
| human
| [[IL17A|IL17A]] and [[IL17F|IL17F]]
| 
|-
| [[Afelimomab|Afelimomab]]
| 
| F(ab')<sub>2</sub>
| mouse
| [[TNF-α|TNF-α]]
| [[Sepsis|sepsis]]
|-
| [[Afutuzumab|Afutuzumab]]
| 
| mab
| humanized
| [[CD20|CD20]]
| [[Lymphoma|lymphoma]]
|-
| [[Alacizumab_pegol|Alacizumab pegol]]
| 
| F(ab')<sub>2</sub>
| humanized
| [[VEGFR2|VEGFR2]]
| [[Cancer|cancer]]
|-
| [[ALD518|ALD518]]
| 
| 
| humanized
| [[Interleukin_6|IL-6]]
| rheumatoid arthritis
|-
| [[Alemtuzumab|Alemtuzumab]]
| Lemtrada, Campath
| mab
| humanized
| [[CD52|CD52]]
| [[Multiple_sclerosis|Multiple sclerosis]]
|-
| [[Alirocumab|Alirocumab]]
| 
| mab
| human
| [[PCSK9|PCSK9]]
| [[Hypercholesterolemia|hypercholesterolemia]]
|-
| [[Indium_(111In)_altumomab_pentetate|Altumomab pentetate]]
| Hybri-ceaker
| mab
| mouse
| [[Carcinoembryonic_antigen|CEA]]
| colorectal cancer (diagnosis)
|-
| [[Amatuximab|Amatuximab]]
| 
| mab
| chimeric
| [[Mesothelin|mesothelin]]
| cancer
|-
| [[Anatumomab_mafenatox|Anatumomab mafenatox]]
| 
| Fab
| mouse
| [[Tumor-associated_glycoprotein_72|TAG-72]]
| [[Non-small_cell_lung_carcinoma|non-small cell lung carcinoma]]
|-
| [[Anetumab_ravtansine|Anetumab ravtansine]]
| 
| mab
| human
| MSLN
| cancer
|-
| [[Anifrolumab|Anifrolumab]]
| 
| mab
| human
| [[Interferon_receptor|interferon α/β receptor]]
| [[Systemic_lupus_erythematosus|systemic lupus erythematosus]]
|-
| [[Anrukinzumab|Anrukinzumab]]
| 
| mab
| humanized
| [[Interleukin_13|IL-13]]
| asthma
|-
| [[Apolizumab|Apolizumab]]
| 
| mab
| humanized
| [[HLA-DR|HLA-DR]]?
| [[Hematological_cancer|hematological cancers]]
|-
| [[Arcitumomab|Arcitumomab]]
| CEA-Scan
| Fab'
| mouse
| [[Carcinoembryonic_antigen|CEA]]
| gastrointestinal cancers (diagnosis)
|-
| [[Ascrinvacumab|Ascrinvacumab]]
| 
| mab
| human
| activin receptor-like kinase 1
| cancer
|-
| [[Aselizumab|Aselizumab]]
| 
| mab
| humanized
| [[L-selectin|L-selectin]] (CD62L)
| severely injured patients
|-
| [[Atezolizumab|Atezolizumab]]
| 
| mab
| humanized
| [[CD274|CD274]]
| cancer
|-
| [[Atinumab|Atinumab]]
| 
| mab
| human
| [[RTN4|RTN4]]
| 
|-
| [[Atlizumab|Atlizumab]] (= tocilizumab)
| Actemra, RoActemra
| mab
| humanized
| [[IL-6_receptor|IL-6 receptor]]
| rheumatoid arthritis
|-
| [[Atorolimumab|Atorolimumab]]
| 
| mab
| human
| [[Rhesus_factor|Rhesus factor]]
| [[Hemolytic_disease_of_the_newborn|hemolytic disease of the newborn]]{{Citation needed|date=November 2009}}
|-
| [[Avelumab|Avelumab]]
| 
| mab
| human
| [[CD274|CD274]]
| 
|-
| [[Bapineuzumab|Bapineuzumab]]
| 
| mab
| humanized
| [[Beta_amyloid|beta amyloid]]
| [[Alzheimer's_disease|Alzheimer's disease]]
|-
| [[Basiliximab|Basiliximab]]
| Simulect
| mab
| chimeric
| [[CD25|CD25]] (α chain of [[Interleukin_2|IL-2]] receptor)
| prevention of organ [[Transplant_rejection|transplant rejections]]
|-
| [[Bavituximab|Bavituximab]]
| 
| mab
| chimeric
| [[Phosphatidylserine|phosphatidylserine]]
| cancer, viral infections
|-
| [[Bectumomab|Bectumomab]]
| LymphoScan
| Fab'
| mouse
| [[CD22|CD22]]
| [[Non-Hodgkin's_lymphoma|non-Hodgkin's lymphoma]] (detection)
|-
| [[Begelomab|Begelomab]]
| 
| mab
| mouse
| [[Dipeptidylpeptidase_4|DPP4]]
| 
|-
| [[Belimumab|Belimumab]]
| Benlysta, LymphoStat-B
| mab
| human
| [[B-cell_activating_factor|BAFF]]
| non-Hodgkin lymphoma etc.
|-
| [[Benralizumab|Benralizumab]]
| 
| mab
| humanized
| [[CD125|CD125]]
| asthma
|-
| [[Bertilimumab|Bertilimumab]]
| 
| mab
| human
| [[CCL11|CCL11]] (eotaxin-1)
| severe allergic disorders
|-
| [[Besilesomab|Besilesomab]]
| Scintimun
| mab
| mouse
| [[Carcinoembryonic_antigen|CEA]]-related antigen
| inflammatory lesions and metastases (detection)
|-
| [[Bevacizumab|Bevacizumab]]
| Avastin
| mab
| humanized
| [[Vascular_endothelial_growth_factor_A|VEGF-A]]
| metastatic cancer, [[Retinopathy_of_prematurity|retinopathy of prematurity]]
|-
| [[Bezlotoxumab|Bezlotoxumab]]
| 
| mab
| human
| ''[[Clostridium_difficile_(bacteria)|Clostridium difficile]]''
| [[Clostridium_difficile_colitis|''Clostridium difficile'' colitis]]
|-
| [[Biciromab|Biciromab]]
| FibriScint
| Fab'
| mouse
| [[Fibrin|fibrin]] II, beta chain
| [[Thromboembolism|thromboembolism]] (diagnosis)
|-
| [[Bimagrumab|Bimagrumab]]
| 
| mab
| human
| [[ACVR2B|ACVR2B]]
| [[Myostatin|myostatin]] inhibitor
|-
| [[Bimekizumab|Bimekizumab]]
| 
| mab
| humanized
| [[Interleukin_17a|IL 17A]] and [[Interleukin_17f|IL 17F]]
| 
|-
| [[Bivatuzumab_mertansine|Bivatuzumab mertansine]]
| 
| mab
| humanized
| [[CD44|CD44]] v6
| [[Squamous_cell_carcinoma|squamous cell carcinoma]]
|-
| [[Bleselumab|Bleselumab]]
| 
| mab
| human
| [[CD40|CD40]]
| 
|-
| [[Blinatumomab|Blinatumomab]]
| 
| BiTE
| mouse
| [[CD19|CD19]]
| pre-B [[Acute_lymphoblastic_leukemia|ALL]] (CD19+)
|-
| [[Blontuvetmab|Blontuvetmab]]
| Blontress
| mab
| veterinary
| [[CD20|CD20]]
| 
|-
| [[Blosozumab|Blosozumab]]
| 
| mab
| humanized
| [[SOST|SOST]]
| osteoporosis
|-
| [[Bococizumab|Bococizumab]]
| 
| mab
| humanized
| neural apoptosis-regulated proteinase 1
| dyslipidemia
|-
| [[Brazikumab|Brazikumab]]
| 
| mab
| human
| [[Interleukin_23|IL23]]
| Crohn's disease
|-
| [[Brentuximab_vedotin|Brentuximab vedotin]]
| 
| mab
| chimeric
| [[CD30|CD30]] (TNFRSF8)
| hematologic cancers
|-
| [[Briakinumab|Briakinumab]]
| 
| mab
| human
| [[Interleukin-12|IL-12]], [[Interleukin-23|IL-23]]
| [[Psoriasis|psoriasis]], [[Rheumatoid_arthritis|rheumatoid arthritis]], [[Inflammatory_bowel_disease|inflammatory bowel diseases]], [[Multiple_sclerosis|multiple sclerosis]]
|-
| [[Brodalumab|Brodalumab]]
| 
| mab
| human
| [[Interleukin-17|IL-17]]
| inflammatory diseases
|-
| [[Brolucizumab|Brolucizumab]]
| 
| mab
| humanized
| [[Vascular_endothelial_growth_factor_A|VEGFA]]
| wet age-related macular degeneration
|-
| [[Brontictuzumab|Brontictuzumab]]
| 
| mab
| humanized
| Notch 1
| cancer
|-
| [[Burosumab|Burosumab]]
| 
| mab
| human
| [[Fibroblast_growth_factor_23|FGF 23]]
| [[X-linked_hypophosphatemia|X-linked hypophosphatemia]]
|-
| [[Cabiralizumab|Cabiralizumab]]
| 
| mab
| humanized
| [[Colony_stimulating_factor_1_receptor|CSF1R]]
| 
|-
| [[Canakinumab|Canakinumab]]
| Ilaris
| mab
| human
| [[Interleukin_1|IL-1]]?
| rheumatoid arthritis
|-
| [[Cantuzumab_mertansine|Cantuzumab mertansine]]
| 
| mab
| humanized
| [[Mucin|mucin]] CanAg
| colorectal cancer etc.
|-
| [[Cantuzumab_ravtansine|Cantuzumab ravtansine]]
| 
| mab
| humanized
| MUC1
| cancers
|-
| [[Caplacizumab|Caplacizumab]]
| 
| mab
| humanized
| VWF
| [[Thrombotic_thrombocytopenic_purpura|thrombotic thrombocytopenic purpura]], [[Thrombosis|thrombosis]]
|-
| [[Capromab_pendetide|Capromab pendetide]]
| Prostascint
| mab
| mouse
| prostatic carcinoma cells
| prostate cancer (detection)
|-
| [[Carlumab|Carlumab]]
| 
| mab
| human
| [[MCP-1|MCP-1]]
| oncology/immune indications
|-
| [[Carotuximab|Carotuximab]]
| 
| mab
| chimeric
| [[Endoglin|endoglin]]
| 
|-
| [[Catumaxomab|Catumaxomab]]
| Removab
| 3funct
| rat/mouse hybrid
| [[EpCAM|EpCAM]], [[CD3_(immunology)|CD3]]
| ovarian cancer, malignant [[Ascites|ascites]], gastric cancer
|-
| [[CBR96-doxorubicin_immunoconjugate|cBR96-doxorubicin immunoconjugate]]
| 
| mab
| humanized
| [[Lewis_antigen_system|Lewis-Y antigen]]
| cancer
|-
| [[Cedelizumab|Cedelizumab]]
| 
| mab
| humanized
| [[CD4|CD4]]
| prevention of organ transplant rejections, treatment of autoimmune diseases
|-
| [[Cergutuzumab_amunaleukin|Cergutuzumab amunaleukin]]
| 
| mab
| humanized
| [[Interleukin_2|IL2]]
| 
|-
| [[Certolizumab_pegol|Certolizumab pegol]]
| Cimzia
| Fab'
| humanized
| [[TNF-α|TNF-α]]
| [[Crohn's_disease|Crohn's disease]] [[Rheumatoid_arthritis|Rheumatoid arthritis]] [[Axial_spondyloarthritis|axial spondyloarthritis]] [[Psoriasis_arthritis|psoriasis arthritis]]
|-
| [[Cetuximab|Cetuximab]]
| Erbitux
| mab
| chimeric
| [[Epidermal_growth_factor_receptor|EGFR]]
| metastatic [[Colorectal_cancer|colorectal cancer]] and [[Head_and_neck_cancer|head and neck cancer]]
|-
| [[Citatuzumab_bogatox|Citatuzumab bogatox]]
| 
| Fab
| humanized
| [[EpCAM|EpCAM]]
| ovarian cancer and other solid tumors
|-
| [[Cixutumumab|Cixutumumab]]
| 
| mab
| human
| [[Insulin-like_growth_factor_1_receptor|IGF-1 receptor (CD221)]]
| solid tumors
|-
| [[Clazakizumab|Clazakizumab]]
| 
| mab
| humanized
| ''Oryctolagus cuniculus''
| rheumatoid arthritis
|-
| [[Clenoliximab|Clenoliximab]]
| 
| mab
| chimeric
| [[CD4|CD4]]
| rheumatoid arthritis
|-
| [[Clivatuzumab_tetraxetan|Clivatuzumab tetraxetan]]
| hPAM4-Cide
| mab
| humanized
| [[MUC1|MUC1]]
| [[Pancreatic_cancer|pancreatic cancer]]
|-
| [[Codrituzumab|Codrituzumab]]
| 
| mab
| humanized
| [[Glypican_3|glypican 3]]
| cancer
|-
| [[Coltuximab_ravtansine|Coltuximab ravtansine]]
| 
| mab
| chimeric
| [[CD19|CD19]]
| cancer
|-
| [[Conatumumab|Conatumumab]]
| 
| mab
| human
| [[TRAIL-R2|TRAIL-R2]]
| cancer
|-
| [[Concizumab|Concizumab]]
| 
| mab
| humanized
| [[Tissue_factor_pathway_inhibitor|TFPI]]
| [[Bleeding|bleeding]]
|-
| [[Crenezumab|Crenezumab]]
| 
| mab
| humanized
| [[1-40-beta-amyloid|1-40-β-amyloid]]
| [[Alzheimer's_disease|Alzheimer's disease]]
|-
| [[Crotedumab|Crotedumab]]
| 
| mab
| human
| [[Glucagon_receptor|GCGR]]
| diabetes
|-
| [[CR6261|CR6261]]
| 
| mab
| human
| [[Hemagglutinin_(influenza)|Influenza A hemagglutinin]]
| infectious disease/influenza A
|-
| [[Dacetuzumab|Dacetuzumab]]
| 
| mab
| humanized
| [[CD40|CD40]]
| hematologic cancers
|-
| [[Daclizumab|Daclizumab]]
| Zenapax
| mab
| humanized
| [[CD25|CD25]] (α chain of [[Interleukin_2|IL-2]] receptor)
| prevention of organ transplant rejections
|-
| [[Dalotuzumab|Dalotuzumab]]
| 
| mab
| humanized
| [[Insulin-like_growth_factor_1_receptor|IGF-1 receptor (CD221)]]
| cancer etc.
|-
| [[Dapirolizumab_pegol|Dapirolizumab pegol]]
| 
| mab
| humanized
| [[CD154|CD154 (CD40L)]]
| 
|-
| [[Daratumumab|Daratumumab]]
| 
| mab
| human
| [[CD38|CD38]] (cyclic ADP ribose hydrolase)
| cancer
|-
| [[Dectrekumab|Dectrekumab]]
| 
| mab
| human
| [[Interleukin_13|IL-13]]
| 
|-
| [[Demcizumab|Demcizumab]]
| 
| mab
| humanized
| DLL4
| cancer
|-
| [[Denintuzumab_mafodotin|Denintuzumab mafodotin]]
| 
| mab
| humanized
| [[CD19|CD19]]
| cancer
|-
| [[Denosumab|Denosumab]]
| Prolia
| mab
| human
| [[RANKL|RANKL]]
| [[Osteoporosis|osteoporosis]], bone metastases etc.
|-
| [[Depatuxizumab_mafodotin|Depatuxizumab mafodotin]]
| 
| mab
| chimeric/humanized
| EGFR
| cancer
|-
| [[Iodine_(131_I)_derlotuximab_biotin|Derlotuximab biotin]]
| 
| mab
| chimeric
| histone complex
| recurrent [[Glioblastoma_multiforme|glioblastoma multiforme]]
|-
| [[Detumomab|Detumomab]]
| 
| mab
| mouse
| B-lymphoma cell
| lymphoma
|-
| [[Dinutuximab|Dinutuximab]]
| 
| mab
| chimeric
| [[GD2|GD2 ganglioside]]
| [[Neuroblastoma|neuroblastoma]]
|-
| [[Diridavumab|Diridavumab]]
| 
| mab
| human
| hemagglutinin
| [[Influenza_A|influenza A]]
|-
| [[Domagrozumab|Domagrozumab]]
| 
| mab
| humanized
| [[Growth_differentiation_factor_8|GDF-8]]
| [[Duchenne_muscular_dystrophy|Duchenne muscular dystrophy]]
|-
| [[Dorlimomab_aritox|Dorlimomab aritox]]
| 
| F(ab')<sub>2</sub>
| mouse
| 
| 
|-
| [[Drozitumab|Drozitumab]]
| 
| mab
| human
| [[TNFRSF10B|DR5]]
| cancer etc.
|-
| [[Duligotumab|Duligotumab]]
| 
| mab
| human
| [[HER3|ERBB3 (HER3)]]
| testicular cancer
|-
| [[Dupilumab|Dupilumab]]
| 
| mab
| human
| [[Interleukin_4|IL4]]
| atopic diseases
|-
| [[Durvalumab|Durvalumab]]
| 
| mab
| human
| [[CD274|CD274]]
| cancer
|-
| [[Dusigitumab|Dusigitumab]]
| 
| mab
| human
| [[Insulin-like_growth_factor_II|ILGF2]]
| cancer
|-
| [[Ecromeximab|Ecromeximab]]
| 
| mab
| chimeric
| GD3 [[Ganglioside|ganglioside]]
| malignant melanoma
|-
| [[Eculizumab|Eculizumab]]
| Soliris
| mab
| humanized
| [[Complement_component_5|C5]]
| [[Paroxysmal_nocturnal_hemoglobinuria|paroxysmal nocturnal hemoglobinuria]], atypical HUS
|-
| [[Edobacomab|Edobacomab]]
| 
| mab
| mouse
| [[Endotoxin|endotoxin]]
| sepsis caused by [[Gram-negative|Gram-negative]] bacteria
|-
| [[Edrecolomab|Edrecolomab]]
| Panorex
| mab
| mouse
| [[EpCAM|EpCAM]]
| colorectal carcinoma
|-
| [[Efalizumab|Efalizumab]]
| Raptiva
| mab
| humanized
| [[LFA-1|LFA-1]] ([[CD11a|CD11a]])
| [[Psoriasis|psoriasis]] (blocks [[T-cell|T-cell]] migration)
|-
| [[Efungumab|Efungumab]]
| Mycograb
| scFv
| human
| [[Hsp90|Hsp90]]
| invasive [[Candidiasis|''Candida'' infection]]
|-
| [[Eldelumab|Eldelumab]]
| 
| mab
| human
| [[Interferon|interferon]] gamma-induced protein
| [[Crohn's_disease|Crohn's disease]], [[Ulcerative_colitis|ulcerative colitis]]
|-
| [[Elgemtumab|Elgemtumab]]
| 
| mab
| human
| [[ERBB3|ERBB3]] (HER3)
| cancer
|-
| [[Elotuzumab|Elotuzumab]]
| 
| mab
| humanized
| [[SLAMF7|SLAMF7]]
| [[Multiple_myeloma|multiple myeloma]]
|-
| [[Elsilimomab|Elsilimomab]]
| 
| mab
| mouse
| [[Interleukin_6|IL-6]]
| 
|-
| [[Emactuzumab|Emactuzumab]]
| 
| mab
| humanized
| [[Colony_stimulating_factor_1_receptor|CSF1R]]
| cancer
|-
| [[Emibetuzumab|Emibetuzumab]]
| 
| mab
| humanized
| [[HHGFR|HHGFR]]
| cancer
|-
| [[Emicizumab|Emicizumab]]
| 
| mab
| humanized
| activated [[Coagulation_factor_IX|F9]], [[Coagulation_factor_X|F10]]
| [[Haemophilia_A|haemophilia A]]
|-
| [[Enavatuzumab|Enavatuzumab]]
| 
| mab
| humanized
| [[TWEAK_receptor|TWEAK receptor]]
| cancer etc.
|-
| [[Enfortumab_vedotin|Enfortumab vedotin]]
| mab
| human
| [[AGS-22M6|AGS-22M6]]
| cancer expressing Nectin-4
|-
| [[Enlimomab_pegol|Enlimomab pegol]]
| 
| mab
| mouse
| [[ICAM-1|ICAM-1]] (CD54)
| 
|-
| [[Enoblituzumab|Enoblituzumab]]
| 
| mab
| humanized
| [[CD276|CD276]]
| cancer
|-
| [[Enokizumab|Enokizumab]]
| 
| mab
| humanized
| [[Interleukin_9|IL9]]
| [[Asthma|asthma]]
|-
| [[Enoticumab|Enoticumab]]
| 
| mab
| human
| [[DLL4|DLL4]]
| 
|-
| [[Ensituximab|Ensituximab]]
| 
| mab
| chimeric
| [[5AC|5AC]]
| cancer
|-
| [[Epitumomab_cituxetan|Epitumomab cituxetan]]
| 
| mab
| mouse
| episialin
| 
|-
| [[Epratuzumab|Epratuzumab]]
| 
| mab
| humanized
| [[CD22|CD22]]
| cancer, [[Systemic_lupus_erythematosus|SLE]]
|-
| [[Erenumab|Erenumab]]
| 
| mab
| human
| [[Calcitonin_gene-related_peptide_receptor|CGRP]]
| migraine
|-
| [[Erlizumab|Erlizumab]]
| 
| F(ab')<sub>2</sub>
| humanized
| [[ITGB2|ITGB2]] (CD18)
| [[Heart_attack|heart attack]], [[Stroke|stroke]], [[Traumatic_shock|traumatic shock]]
|-
| [[Ertumaxomab|Ertumaxomab]]
| Rexomun
| 3funct
| rat/mouse hybrid
| [[HER2/neu|HER2/neu]], [[CD3_(immunology)|CD3]]
| breast cancer etc.
|-
| [[Etaracizumab|Etaracizumab]]
| Abegrin
| mab
| humanized
| [[Integrin|integrin]] [[Alpha-v_beta-3|α<sub>v</sub>β<sub>3</sub>]]
| melanoma, [[Prostate_cancer|prostate cancer]], [[Ovarian_cancer|ovarian cancer]] etc.
|-
| [[Etrolizumab|Etrolizumab]]
| 
| mab
| humanized
| [[Integrin|integrin]] [[Alpha-7_beta-7|α<sub>7</sub> β<sub>7</sub>]]
| [[Inflammatory_bowel_disease|inflammatory bowel disease]]
|-
| [[Evinacumab|Evinacumab]]
| 
| mab
| human
| angiopoietin 3
| [[Dyslipidemia|dyslipidemia]]
|-
| [[Evolocumab|Evolocumab]]
| 
| mab
| human
| [[PCSK9|PCSK9]]
| [[Hypercholesterolemia|hypercholesterolemia]]
|-
| [[Exbivirumab|Exbivirumab]]
| 
| mab
| human
| [[Hepatitis_B|hepatitis B]] surface antigen
| hepatitis B
|-
| [[Technetium_(99mTc)_fanolesomab|Fanolesomab]]
| NeutroSpec
| mab
| mouse
| [[CD15|CD15]]
| [[Appendicitis|appendicitis]] (diagnosis)
|-
| [[Faralimomab|Faralimomab]]
| 
| mab
| mouse
| [[Interferon_receptor|interferon receptor]]
| 
|-
| [[Farletuzumab|Farletuzumab]]
| 
| mab
| humanized
| [[Folate_receptor_1|folate receptor 1]]
| ovarian cancer
|-
| [[Fasinumab|Fasinumab]]
| 
| mab
| human
| [[Nerve_growth_factor|HNGF]]
| acute sciatic pain
|-
| [[FBTA05|FBTA05]]
| Lymphomun
| 3funct
| rat/mouse hybrid
| [[CD20|CD20]]
| [[Chronic_lymphocytic_leukaemia|chronic lymphocytic leukaemia]]
|-
| [[Felvizumab|Felvizumab]]
| 
| mab
| humanized
| [[Respiratory_syncytial_virus|respiratory syncytial virus]]
| respiratory syncytial virus infection
|-
| [[Fezakinumab|Fezakinumab]]
| 
| mab
| human
| [[Interleukin_22|IL-22]]
| rheumatoid arthritis, [[Psoriasis|psoriasis]]
|-
| [[Fibatuzumab|Fibatuzumab]]
| 
| mab
| humanized
| [[EPHA3|ephrin receptor A3]]
| 
|-
| [[Ficlatuzumab|Ficlatuzumab]]
| 
| mab
| humanized
| [[Hepatocyte_growth_factor|HGF]]
| cancer etc.
|-
| [[Figitumumab|Figitumumab]]
| 
| mab
| human
| [[Insulin-like_growth_factor_1_receptor|IGF-1 receptor (CD221)]]
| [[Adrenocortical_carcinoma|adrenocortical carcinoma]], [[Non-small_cell_lung_carcinoma|non-small cell lung carcinoma]] etc.
|-
| [[Firivumab|Firivumab]]
| 
| mab
| human
| influenza A virus hemagglutinin
| 
|-
| [[Flanvotumab|Flanvotumab]]
| 
| mab
| human
| [[TYRP1|TYRP1]](glycoprotein 75)
| melanoma
|-
| [[Fletikumab|Fletikumab]]
| 
| mab
| human
| [[Interleukin_20|IL 20]]
| rheumatoid arthritis
|-
| [[Fontolizumab|Fontolizumab]]
| HuZAF
| mab
| humanized
| [[IFN-γ|IFN-γ]]
| Crohn's disease etc.
|-
| [[Foralumab|Foralumab]]
| mab
| human
| [[CD3_epsilon|CD3 epsilon]]
| 
|-
| [[Foravirumab|Foravirumab]]
| 
| mab
| human
| [[Rabies|rabies]] virus glycoprotein
| rabies (prophylaxis)
|-
| [[Fresolimumab|Fresolimumab]]
| 
| mab
| human
| [[TGF-β|TGF-β]]
| [[Idiopathic_pulmonary_fibrosis|idiopathic pulmonary fibrosis]], [[Focal_segmental_glomerulosclerosis|focal segmental glomerulosclerosis]], cancer
|-
| [[Fulranumab|Fulranumab]]
| 
| mab
| human
| [[Nerve_growth_factor|NGF]]
| pain
|-
| [[Futuximab|Futuximab]]
| 
| mab
| chimeric
| [[Epidermal_growth_factor_receptor|EGFR]]
| cancer
|-
| [[Galcanezumab|Galcanezumab]]
| 
| mab
| humanized
| [[Calcitonin|calcitonin]]
| [[Migraine|migraine]]
|-
| [[Galiximab|Galiximab]]
| 
| mab
| chimeric
| [[CD80|CD80]]
| [[B-cell_lymphoma|B-cell lymphoma]]
|-
| [[Ganitumab|Ganitumab]]
| 
| mab
| human
| [[Insulin-like_growth_factor_1_receptor|IGF-1 receptor (CD221)]]
| cancer
|-
| [[Gantenerumab|Gantenerumab]]
| 
| mab
| human
| [[Beta_amyloid|beta amyloid]]
| Alzheimer's disease
|-
| [[Gavilimomab|Gavilimomab]]
| 
| mab
| mouse
| [[CD147|CD147]] (basigin)
| [[Graft_versus_host_disease|graft versus host disease]]
|-
| [[Gemtuzumab_ozogamicin|Gemtuzumab ozogamicin]]
| Mylotarg
| mab
| humanized
| [[CD33|CD33]]
| [[Acute_myelogenous_leukemia|acute myelogenous leukemia]]
|-
| [[Gevokizumab|Gevokizumab]]
| 
| mab
| humanized
| [[IL-1β|IL-1β]]
| [[Diabetes|diabetes]] etc.
|-
| [[Girentuximab|Girentuximab]]
| Rencarex
| mab
| chimeric
| [[Carbonic_anhydrase_9|carbonic anhydrase 9]] (CA-IX)
| clear cell [[Renal_cell_carcinoma|renal cell carcinoma]]&lt;ref&gt;[http://www.prnewswire.com/news-releases/prometheus-obtains-exclusive-us-commercialization-rights-for-rencarex-121075044.html http://www.prnewswire.com/news-releases/prometheus-obtains-exclusive-us-commercialization-rights-for-rencarex-121075044.html]&lt;/ref&gt;
|-
| [[Glembatumumab_vedotin|Glembatumumab vedotin]]
| 
| mab
| human
| [[GPNMB|GPNMB]]
| melanoma, breast cancer
|-
| [[Golimumab|Golimumab]]
| Simponi
| mab
| human
| [[TNF-α|TNF-α]]
| rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis
|-
| [[Gomiliximab|Gomiliximab]]
| 
| mab
| chimeric
| [[CD23|CD23]] ([[IgE_receptor|IgE receptor]])
| [[Allergic_asthma|allergic asthma]]
|-
| [[Guselkumab|Guselkumab]]
| 
| mab
| human
| [[Interleukin_23|IL23]]
| [[Psoriasis|psoriasis]]
|-
| [[Ibalizumab|Ibalizumab]]
| 
| mab
| humanized
| [[CD4|CD4]]
| [[HIV_infection|HIV infection]]
|-
| [[Ibritumomab_tiuxetan|Ibritumomab tiuxetan]]
| Zevalin
| mab
| mouse
| [[CD20|CD20]]
| non-Hodgkin's lymphoma
|-
| [[Icrucumab|Icrucumab]]
| 
| mab
| human
| [[VEGFR-1|VEGFR-1]]
| cancer etc.
|-
| [[Idarucizumab|Idarucizumab]]
| 
| mab
| humanized
| [[Dabigatran|dabigatran]]
| reversal of anticoagulant effects of dabigatran
|-
| [[Igovomab|Igovomab]]
| Indimacis-125
| F(ab')<sub>2</sub>
| mouse
| [[CA-125|CA-125]]
| ovarian cancer (diagnosis)
|-
| [[IMAB362|IMAB362]]
| 
| mab
| human
| [[CLDN18|CLDN18]].2
| gastrointestinal adenocarcinomas and pancreatic tumor
|-
| [[Imalumab|Imalumab]]
| 
| mab
| human
| [[Macrophage_migration_inhibitory_factor|MIF]]
| cancer
|-
| [[Imciromab|Imciromab]]
| Myoscint
| mab
| mouse
| [[Cardiac|cardiac]] [[Myosin|myosin]]
| [[Cardiac|cardiac]] imaging
|-
| [[Imgatuzumab|Imgatuzumab]]
| 
| mab
| humanized
| [[Epidermal_growth_factor_receptor|EGFR]]
| cancer
|-
| [[Inclacumab|Inclacumab]]
| 
| mab
| human
| selectin P
| cardiovascular disease
|-
| [[Indatuximab_ravtansine|Indatuximab ravtansine]]
| 
| mab
| chimeric
| [[SDC1|SDC1]]
| cancer
|-
| [[Indusatumab_vedotin|Indusatumab vedotin]]
| 
| mab
| human
| [[Guanylate_cyclase_2C|GUCY2C]]
| cancer
|-
| [[Inebilizumab|Inebilizumab]]
| 
| mab
| humanized
| [[CD19|CD19]]
| cancer, [[Systemic_sclerosis|systemic sclerosis]], [[Multiple_sclerosis|multiple sclerosis]]
|-
| [[Infliximab|Infliximab]]
| Remicade
| mab
| chimeric
| [[TNF-α|TNF-α]]
| rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis, Crohn's disease, ulcerative colitis
|-
| [[Intetumumab|Intetumumab]]
| 
| mab
| human
| [[CD51|CD51]]
| solid tumors (prostate cancer, melanoma)
|-
| [[Inolimomab|Inolimomab]]
| 
| mab
| mouse
| [[CD25|CD25]] (α chain of [[Interleukin_2|IL-2]] receptor)
| graft versus host disease
|-
| [[Inotuzumab_ozogamicin|Inotuzumab ozogamicin]]
| 
| mab
| humanized
| [[CD22|CD22]]
| [[Acute_lymphoblastic_leukemia|ALL]]
|-
| [[Ipilimumab|Ipilimumab]]
| Yervoy
| mab
| human
| [[CD152|CD152]]
| [[Melanoma|melanoma]]
|-
| [[Iratumumab|Iratumumab]]
| 
| mab
| human
| [[CD30|CD30]] (TNFRSF8)
| [[Hodgkin's_lymphoma|Hodgkin's lymphoma]]
|-
| [[Isatuximab|Isatuximab]]
| 
| mab
| chimeric
| [[CD38|CD38]]
| cancer
|-
| [[Itolizumab|Itolizumab]]
| 
| mab
| humanized
| [[CD6|CD6]]
| 
|-
| [[Ixekizumab|Ixekizumab]]
| 
| mab
| humanized
| [[Interleukin_17a|IL 17A]]
| autoimmune diseases
|-
| [[Keliximab|Keliximab]]
| 
| mab
| chimeric
| [[CD4|CD4]]
| chronic asthma
|-
| [[Labetuzumab|Labetuzumab]]
| CEA-Cide
| mab
| humanized
| [[Carcinoembryonic_antigen|CEA]]
| [[Colorectal_cancer|colorectal cancer]]
|-
| [[Lampalizumab|Lampalizumab]]
| 
| mab
| humanized
| [[Complement_factor_D|CFD]]
| geographic atrophy secondary to age-related macular degeneration
|-
| [[Lanadelumab|Lanadelumab]]
| 
| mab
| human
| [[Kallikrein|kallikrein]]
| [[Angioedema|angioedema]]
|-
| [[Landogrozumab|Landogrozumab]]
| 
| mab
| humanized
| [[Growth_differentiation_factor_8|GDF-8]]
| muscle wasting disorders
|-
| [[Laprituximab_emtansine|Laprituximab emtansine]]
| 
| mab
| chimeric
| [[Epidermal_growth_factor_receptor|EGFR]]
| 
|-
| [[Lebrikizumab|Lebrikizumab]]
| 
| mab
| humanized
| [[Interleukin_13|IL-13]]
| [[Asthma|asthma]]
|-
| [[Lemalesomab|Lemalesomab]]
| 
| mab
| mouse
| NCA-90 (granulocyte antigen)
| diagnostic agent
|-
| [[Lendalizumab|Lendalizumab]]
| 
| mab
| humanized
| [[Complement_5|C5]]
| 
|-
| [[Lenzilumab|Lenzilumab]]
| 
| mab
| human
| [[Colony_stimulating_factor_2|CSF2]]
| 
|-
| [[Lerdelimumab|Lerdelimumab]]
| 
| mab
| human
| [[TGF_beta_2|TGF beta 2]]
| reduction of scarring after [[Glaucoma_surgery|glaucoma surgery]]
|-
| [[Lexatumumab|Lexatumumab]]
| 
| mab
| human
| [[TRAIL-R2|TRAIL-R2]]
| cancer
|-
| [[Libivirumab|Libivirumab]]
| 
| mab
| human
| [[Hepatitis_B|hepatitis B]] surface antigen
| hepatitis B
|-
| [[Lifastuzumab_vedotin|Lifastuzumab vedotin]]
| 
| mab
| humanized
| phosphate-sodium co-transporter
| cancer
|-
| [[Ligelizumab|Ligelizumab]]
| 
| mab
| humanized
| [[IGHE|IGHE]]
| severe asthma and [[Chronic_spontaneous_urticaria|chronic spontaneous urticaria]]
|-
| [[Lutetium_(177_Lu)_lilotomab_satetraxetan|Lilotomab satetraxetan]]
| 
| mab
| mouse
| [[CD37|CD37]]
| cancer
|-
| [[Lintuzumab|Lintuzumab]]
| 
| mab
| humanized
| [[CD33|CD33]]
| cancer
|-
| [[Lirilumab|Lirilumab]]
| 
| mab
| human
| [[KIR2D|KIR2D]]
| solid and hematological cancers
|-
| [[Lodelcizumab|Lodelcizumab]]
| 
| mab
| humanized
| [[PCSK9|PCSK9]]
| [[Hypercholesterolemia|hypercholesterolemia]]
|-
| [[Lokivetmab|Lokivetmab]]
| 
| mab
| veterinary
| ''[[Canis_lupus_familiaris|Canis lupus familiaris]]'' [[Interleukin_31|IL31]]
| 
|-
| [[Lorvotuzumab_mertansine|Lorvotuzumab mertansine]]
| 
| mab
| humanized
| [[CD56|CD56]]
| cancer
|-
| [[Lucatumumab|Lucatumumab]]
| 
| mab
| human
| [[CD40|CD40]]
| [[Multiple_myeloma|multiple myeloma]], [[Non-Hodgkin's_lymphoma|non-Hodgkin's lymphoma]], [[Hodgkin's_lymphoma|Hodgkin's lymphoma]]
|-
| [[Lulizumab_pegol|Lulizumab pegol]]
| 
| mab
| humanized
| [[CD28|CD28]]
| autoimmune diseases
|-
| [[Lumiliximab|Lumiliximab]]
| 
| mab
| chimeric
| [[CD23|CD23]] ([[IgE_receptor|IgE receptor]])
| [[Chronic_lymphocytic_leukemia|chronic lymphocytic leukemia]]
|-
| [[Lumretuzumab|Lumretuzumab]]
| 
| mab
| humanized
| [[ERBB3|ERBB3]] (HER3)
| cancer
|-
| [[MABp1|MABp1]]
| Xilonix
| mab
| human
| [[IL1A|IL1A]]
| colorectal cancer
|-
| [[Mapatumumab|Mapatumumab]]
| 
| mab
| human
| [[TRAIL|TRAIL]]-R1
| cancer
|-
| [[Margetuximab|Margetuximab]]
| 
| mab
| humanized
| [[Ch4D5|ch4D5]]
| cancer
|-
| [[Maslimomab|Maslimomab]]
| 
| 
| mouse
| T-cell receptor
| 
|-
| [[Mavrilimumab|Mavrilimumab]]
| 
| mab
| human
| [[GMCSF_receptor_alpha-chain|GMCSF receptor α-chain]]
| [[Rheumatoid_arthritis|rheumatoid arthritis]]
|-
| [[Matuzumab|Matuzumab]]
| 
| mab
| humanized
| [[Epidermal_growth_factor_receptor|EGFR]]
| colorectal, lung and stomach cancer
|-
| [[Mepolizumab|Mepolizumab]]
| Bosatria
| mab
| humanized
| [[Interleukin_5|IL-5]]
| asthma and white blood cell diseases
|-
| [[Metelimumab|Metelimumab]]
| 
| mab
| human
| [[TGF_beta_1|TGF beta 1]]
| [[Systemic_scleroderma|systemic scleroderma]]
|-
| [[Milatuzumab|Milatuzumab]]
| 
| mab
| humanized
| [[CD74|CD74]]
| multiple myeloma and other hematological malignancies
|-
| [[Minretumomab|Minretumomab]]
| 
| mab
| mouse
| [[Tumor-associated_glycoprotein_72|TAG-72]]
| tumor detection (and therapy?)
|-
| [[Mirvetuximab_soravtansine|Mirvetuximab soravtansine]]
| 
| mab
| chimeric
| [[Folate_receptor_alpha|folate receptor alpha]]
| cancer
|-
| [[Mitumomab|Mitumomab]]
| 
| mab
| mouse
| GD3 [[Ganglioside|ganglioside]]
| [[Small_cell_lung_carcinoma|small cell lung carcinoma]]
|-
| [[Mogamulizumab|Mogamulizumab]]
| 
| mab
| humanized
| [[CCR4|CCR4]]
| cancer
|-
| [[Monalizumab|Monalizumab]]
| 
| mab
| humanized
| [[KLRC1|KLRC1]]
| 
|-
| [[Morolimumab|Morolimumab]]
| 
| mab
| human
| [[Rhesus_factor|Rhesus factor]]
| 
|-
| [[Motavizumab|Motavizumab]]
| Numax
| mab
| humanized
| [[Respiratory_syncytial_virus|respiratory syncytial virus]]
| respiratory syncytial virus (prevention)
|-
| [[Moxetumomab_pasudotox|Moxetumomab pasudotox]]
| 
| mab
| mouse
| [[CD22|CD22]]
| cancer
|-
| [[Muromonab-CD3|Muromonab-CD3]]
| Orthoclone OKT3
| mab
| mouse
| [[CD3_(immunology)|CD3]]
| prevention of organ transplant rejections
|-
| [[Nacolomab_tafenatox|Nacolomab tafenatox]]
| 
| Fab
| mouse
| C242 antigen
| colorectal cancer
|-
| [[Namilumab|Namilumab]]
| 
| mab
| human
| [[CSF2|CSF2]]
| 
|-
| [[Naptumomab_estafenatox|Naptumomab estafenatox]]
| 
| Fab
| mouse
| [[5T4|5T4]]
| non-small cell lung carcinoma, [[Renal_cell_carcinoma|renal cell carcinoma]]
|-
| [[Naratuximab_emtansine|Naratuximab emtansine]]
| 
| mab
| chimeric
| [[CD37|CD37]]
| 
|-
| [[Narnatumab|Narnatumab]]
| 
| mab
| human
| RON
| cancer
|-
| [[Natalizumab|Natalizumab]]
| Tysabri
| mab
| humanized
| [[Integrin|integrin]] α<sub>4</sub>
| [[Multiple_sclerosis|multiple sclerosis]], Crohn's disease
|-
| [[Navicixizumab|Navicixizumab]]
| 
| mab
| chimeric/humanized
| [[DLL4|DLL4]]
| 
|-
| [[Navivumab|Navivumab]]
| 
| mab
| human
| [[Influenza_A_virus|influenza A virus]] [[Hemagglutinin_HA|hemagglutinin HA]]
| 
|-
| [[Nebacumab|Nebacumab]]
| 
| mab
| human
| [[Endotoxin|endotoxin]]
| sepsis
|-
| [[Necitumumab|Necitumumab]]
| 
| mab
| human
| [[Epidermal_growth_factor_receptor|EGFR]]
| non-small cell lung carcinoma
|-
| [[Nemolizumab|Nemolizumab]]
| 
| mab
| humanized
| [[IL31RA|IL31RA]]
| [[Eczema|eczema]]
|-
| [[Nerelimomab|Nerelimomab]]
| 
| mab
| mouse
| [[TNF-α|TNF-α]]
| 
|-
| [[Nesvacumab|Nesvacumab]]
| 
| mab
| human
| [[Angiopoietin_2|angiopoietin 2]]
| cancer
|-
| [[Nimotuzumab|Nimotuzumab]]
| Theracim, Theraloc
| mab
| humanized
| [[Epidermal_growth_factor_receptor|EGFR]]
| squamous cell carcinoma, head and neck cancer, [[Nasopharyngeal_cancer|nasopharyngeal cancer]], [[Glioma|glioma]]
|-
| [[Nivolumab|Nivolumab]]
| Opdivo
| mab
| human
| PD-1
| cancer
|-
| [[Technetium_(99mTc)_nofetumomab_merpentan|Nofetumomab merpentan]]
| Verluma
| Fab
| mouse
| 
| cancer (diagnosis)
|-
| [[Obiltoxaximab|Obiltoxaximab]]
| 
| mab
| chimeric
| ''[[Bacillus_anthracis|Bacillus anthracis]]'' anthrax
| ''Bacillus anthracis'' spores
|-
| [[Obinutuzumab|Obinutuzumab]]
| Gazyva
| mab
| humanized
| [[CD20|CD20]]
| [[Chronic_lymphatic_leukemia|Chronic lymphatic leukemia]]
|-
| [[Ocaratuzumab|Ocaratuzumab]]
| 
| mab
| humanized
| [[CD20|CD20]]
| cancer
|-
| [[Ocrelizumab|Ocrelizumab]]
| 
| mab
| humanized
| [[CD20|CD20]]
| rheumatoid arthritis, lupus erythematosus etc.
|-
| [[Odulimomab|Odulimomab]]
| 
| mab
| mouse
| [[LFA-1|LFA-1]] ([[CD11a|CD11a]])
| prevention of organ transplant rejections, immunological diseases
|-
| [[Ofatumumab|Ofatumumab]]
| Arzerra
| mab
| human
| [[CD20|CD20]]
| chronic lymphocytic leukemia etc.
|-
| [[Olaratumab|Olaratumab]]
| 
| mab
| human
| [[Platelet-derived_growth_factor_receptor_alpha|PDGF-R α]]
| cancer
|-
| [[Olokizumab|Olokizumab]]
| 
| mab
| humanized
| [[Interleukin_6|IL6]]
| 
|-
| [[Omalizumab|Omalizumab]]
| Xolair
| mab
| humanized
| [[IgE|IgE]] [[Fc_region|Fc region]]
| allergic asthma
|-
| [[Onartuzumab|Onartuzumab]]
| 
| mab
| humanized
| human scatter factor receptor kinase
| cancer
|-
| [[Ontuxizumab|Ontuxizumab]]
| 
| mab
| chimeric/humanized
| [[Tumor_endothelial_marker_1|TEM1]]
| cancer
|-
| [[Opicinumab|Opicinumab]]
| mab
| human
| LINGO-1
| [[Multiple_sclerosis|multiple sclerosis]]
|-
| [[Oportuzumab_monatox|Oportuzumab monatox]]
| 
| scFv
| humanized
| [[EpCAM|EpCAM]]
| cancer
|-
| [[Oregovomab|Oregovomab]]
| OvaRex
| mab
| mouse
| [[CA-125|CA-125]]
| ovarian cancer
|-
| [[Orticumab|Orticumab]]
| 
| mab
| human
| [[Oxidized_low-density_lipoprotein|oxLDL]]
| 
|-
| [[Otelixizumab|Otelixizumab]]
| 
| mab
| chimeric/humanized
| [[CD3_(immunology)|CD3]]
| diabetes mellitus type 1
|-
| [[Otlertuzumab|Otlertuzumab]]
| 
| mab
| humanized
| [[CD37|CD37]]
| cancer
|-
| [[Oxelumab|Oxelumab]]
| 
| mab
| human
| [[OX-40|OX-40]]
| asthma
|-
| [[Ozanezumab|Ozanezumab]]
| 
| mab
| humanized
| NOGO-A
| ALS and [[Multiple_sclerosis|multiple sclerosis]]
|-
| [[Ozoralizumab|Ozoralizumab]]
| 
| mab
| humanized
| ''[[TNF-α|TNF-α]]''
| inflammation
|-
| [[Pagibaximab|Pagibaximab]]
| 
| mab
| chimeric
| [[Lipoteichoic_acid|lipoteichoic acid]]
| sepsis (''[[Staphylococcus|Staphylococcus]]'')
|-
| [[Palivizumab|Palivizumab]]
| Synagis, Abbosynagis
| mab
| humanized
| F protein of [[Respiratory_syncytial_virus|respiratory syncytial virus]]
| respiratory syncytial virus (prevention)
|-
| [[Pamrevlumab|Pamrevlumab]]
| 
| mab
| human
| [[Connective_tissue_growth_factor|CTGF]]
| idiopathic pulmonary fibrosis (IPF), pancreatic cancer
|-
| [[Panitumumab|Panitumumab]]
| Vectibix
| mab
| human
| [[Epidermal_growth_factor_receptor|EGFR]]
| colorectal cancer
|-
| [[Pankomab|Pankomab]]
| 
| mab
| humanized
| tumor specific glycosylation of [[MUC1|MUC1]]
| ovarian cancer
|-
| [[Panobacumab|Panobacumab]]
| 
| mab
| human
| ''[[Pseudomonas_aeruginosa|Pseudomonas aeruginosa]]''
| ''Pseudomonas aeruginosa'' infection
|-
| [[Parsatuzumab|Parsatuzumab]]
| 
| mab
| human
| [[EGFL7|EGFL7]]
| cancer
|-
| [[Pascolizumab|Pascolizumab]]
| 
| mab
| humanized
| [[Interleukin_4|IL-4]]
| asthma
|-
| [[Pasotuxizumab|Pasotuxizumab]]
| 
| mab
| chimeric/humanized
| [[Folate_hydrolase|folate hydrolase]]
| cancer
|-
| [[Pateclizumab|Pateclizumab]]
| 
| mab
| humanized
| [[Lymphotoxin_alpha|LTA]]
| [[TNF|TNF]]
|-
| [[Patritumab|Patritumab]]
| 
| mab
| human
| ERBB3 ([[HER3|HER3]])
| cancer
|-
| [[Pembrolizumab|Pembrolizumab]]
| 
| mab
| humanized
| [[Programmed_cell_death_1|PDCD1]]
| [[Melanoma|melanoma]] and other cancers
|-
| [[Pemtumomab|Pemtumomab]]
| Theragyn
| 
| mouse
| [[MUC1|MUC1]]
| cancer
|-
| [[Perakizumab|Perakizumab]]
| 
| mab
| humanized
| [[Interleukin_17a|IL 17A]]
| [[Arthritis|arthritis]]
|-
| [[Pertuzumab|Pertuzumab]]
| Omnitarg
| mab
| humanized
| [[HER2/neu|HER2/neu]]
| cancer
|-
| [[Pexelizumab|Pexelizumab]]
| 
| scFv
| humanized
| [[Complement_component_5|C5]]
| reduction of side effects of [[Cardiac_surgery|cardiac surgery]]
|-
| [[Pidilizumab|Pidilizumab]]
| 
| mab
| humanized
| PD-1
| cancer and infectious diseases
|-
| [[Pinatuzumab_vedotin|Pinatuzumab vedotin]]
| 
| mab
| humanized
| [[CD22|CD22]]
| cancer
|-
| [[Pintumomab|Pintumomab]]
| 
| mab
| mouse
| [[Adenocarcinoma|adenocarcinoma]] antigen
| [[Adenocarcinoma|adenocarcinoma]] (imaging)
|-
| [[Placulumab|Placulumab]]
| 
| mab
| human
| human TNF
| pain and inflammatory diseases
|-
| [[Plozalizumab|Plozalizumab]]
| 
| mab
| humanized
| [[Chemokine_receptor_2|CCR2]]
| [[Diabetic_nephropathy|diabetic nephropathy]] and [[Arteriovenous_graft_patency|arteriovenous graft patency]]
|-
| [[Pogalizumab|Pogalizumab]]
| 
| mab
| humanized
| [[Tumor_necrosis_factor_receptor|TNFR]] superfamily member 4
| 
|-
| [[Polatuzumab_vedotin|Polatuzumab vedotin]]
| 
| mab
| humanized
| [[CD79B|CD79B]]
| cancer
|-
| [[Ponezumab|Ponezumab]]
| 
| mab
| humanized
| human [[Beta-amyloid|beta-amyloid]]
| Alzheimer's disease
|-
| [[Prezalizumab|Prezalizumab]]
| 
| mab
| humanized
| [[Inducible_T-cell_co-stimulatory_ligand|ICOSL]]
| 
|-
| [[Priliximab|Priliximab]]
| 
| mab
| chimeric
| [[CD4|CD4]]
| Crohn's disease, multiple sclerosis
|-
| [[Pritoxaximab|Pritoxaximab]]
| 
| mab
| chimeric
| ''[[Escherichia_coli|E. coli]]'' [[Shiga_toxin|shiga toxin]] type-1
| 
|-
| [[Pritumumab|Pritumumab]]
| 
| mab
| human
| [[Vimentin|vimentin]]
| [[Brain_cancer|brain cancer]]
|-
| [[PRO_140|PRO 140]]
| 
| 
| humanized
| [[CCR5|CCR5]]
| HIV infection
|-
| [[Quilizumab|Quilizumab]]
| 
| mab
| humanized
| IGHE
| asthma
|-
| [[Racotumomab|Racotumomab]]
| 
| mab
| mouse
| ''N''-[[Glycolylneuraminic_acid|glycolylneuraminic acid]]
| cancer
|-
| [[Radretumab|Radretumab]]
| 
| mab
| human
| [[Fibronectin|fibronectin]] extra domain-B
| cancer
|-
| [[Rafivirumab|Rafivirumab]]
| 
| mab
| human
| [[Rabies|rabies]] virus glycoprotein
| rabies (prophylaxis)
|-
| [[Ralpancizumab|Ralpancizumab]]
| 
| mab
| humanized
| neural apoptosis-regulated proteinase 1
| [[Dyslipidemia|dyslipidemia]]
|-
| [[Ramucirumab|Ramucirumab]]
| Cyramza
| mab
| human
| [[VEGFR2|VEGFR2]]
| solid tumors
|-
| [[Ranibizumab|Ranibizumab]]
| Lucentis
| Fab
| humanized
| [[VEGF-A|VEGF-A]]
| [[Macular_degeneration|macular degeneration]] (wet form)
|-
| [[Raxibacumab|Raxibacumab]]
| 
| mab
| human
| [[Anthrax|anthrax]] toxin, protective antigen
| anthrax (prophylaxis and treatment)
|-
| [[Refanezumab|Refanezumab]]
| 
| mab
| humanized
| myelin-associated glycoprotein
| recovery of motor function after stroke
|-
| [[Regavirumab|Regavirumab]]
| 
| mab
| human
| [[Cytomegalovirus|cytomegalovirus]] glycoprotein B
| cytomegalovirus infection
|-
| [[Reslizumab|Reslizumab]]
| 
| mab
| humanized
| [[Interleukin_5|IL-5]]
| [[Inflammation|inflammations]] of the airways, skin and gastrointestinal tract
|-
| [[Rilotumumab|Rilotumumab]]
| 
| mab
| human
| [[Hepatocyte_growth_factor|HGF]]
| solid tumors
|-
| [[Rinucumab|Rinucumab]]
| 
| mab
| human
| platelet-derived growth factor receptor beta
| neovascular age-related macular degeneration
|-
| [[Risankizumab|Risankizumab]]
| 
| mab
| humanized
| [[IL23A|IL23A]]
| 
|-
| [[Rituximab|Rituximab]]
| MabThera, Rituxan
| mab
| chimeric
| [[CD20|CD20]]
| lymphomas, [[Leukemia|leukemias]], some autoimmune disorders
|-
| [[Rivabazumab_pegol|Rivabazumab pegol]]
| 
| mab
| humanized
| ''[[Pseudomonas_aeruginosa|Pseudomonas aeruginosa]]'' type III secretion system
| 
|-
| [[Robatumumab|Robatumumab]]
| 
| mab
| human
| [[Insulin-like_growth_factor_1_receptor|IGF-1 receptor (CD221)]]
| cancer
|-
| [[Roledumab|Roledumab]]
| 
| mab
| human
| [[RHD_(gene)|RHD]]
| 
|-
| [[Romosozumab|Romosozumab]]
| 
| mab
| humanized
| [[Sclerostin|sclerostin]]
| [[Osteoporosis|osteoporosis]]
|-
| [[Rontalizumab|Rontalizumab]]
| 
| mab
| humanized
| [[Interferon-alpha|IFN-α]]
| [[Systemic_lupus_erythematosus|systemic lupus erythematosus]]
|-
| [[Rovalpituzumab_tesirine|Rovalpituzumab tesirine]]
| 
| mab
| humanized
| [[Delta-like_ligand_3|DLL3]]
| 
|-
| [[Rovelizumab|Rovelizumab]]
| LeukArrest
| mab
| humanized
| [[CD11|CD11]], [[CD18|CD18]]
| [[Haemorrhagic_shock|haemorrhagic shock]] etc.
|-
| [[Ruplizumab|Ruplizumab]]
| Antova
| mab
| humanized
| [[CD154|CD154]] (CD40L)
| rheumatic diseases
|-
| [[Sacituzumab_govitecan|Sacituzumab govitecan]]
| 
| mab
| humanized
| tumor-associated calcium signal transducer 2
| cancer
|-
| [[Samalizumab|Samalizumab]]
| 
| mab
| humanized
| [[CD200|CD200]]
| cancer
|-
| [[Sapelizumab|Sapelizumab]]
| 
| mab
| humanized
| [[Interleukin_6_receptor|IL6R]]
| 
|-
| [[Sarilumab|Sarilumab]]
| 
| mab
| human
| [[Interleukin_6|IL6]]
| rheumatoid arthritis, [[Ankylosing_spondylitis|ankylosing spondylitis]]
|-
| [[Satumomab_pendetide|Satumomab pendetide]]
| 
| mab
| mouse
| [[Tumor-associated_glycoprotein_72|TAG-72]]
| cancer (diagnosis)
|-
| [[Secukinumab|Secukinumab]]
| 
| mab
| human
| [[Interleukin_17a|IL 17A]]
| [[Uveitis|uveitis]], rheumatoid arthritis [[Psoriasis|psoriasis]]
|-
| [[Seribantumab|Seribantumab]]
| 
| mab
| human
| [[ERBB3|ERBB3]] (HER3)
| cancer
|-
| [[Setoxaximab|Setoxaximab]]
| 
| mab
| chimeric
| ''[[Escherichia_coli|E. coli]]'' [[Shiga_toxin|shiga toxin]] type-2
| 
|-
| [[Sevirumab|Sevirumab]]
| 
| 
| human
| [[Cytomegalovirus|cytomegalovirus]]
| cytomegalovirus infection
|-
| [[Sibrotuzumab|Sibrotuzumab]]
| 
| mab
| humanized
| [[FAP_(gene)|FAP]]
| cancer
|-
| [[SGN-CD19A|SGN-CD19A]]
| 
| mab
| humanized
| [[CD19|CD19]]
| [[Acute_lymphoblastic_leukemia|acute lymphoblastic leukemia]] and B-cell non-Hodgkin lymphoma
|-
| [[SGN-CD33A|SGN-CD33A]]
| 
| mab
| humanized
| [[CD33|CD33]]
| [[Acute_myeloid_leukemia|Acute myeloid leukemia]]
|-
| [[Sifalimumab|Sifalimumab]]
| 
| mab
| humanized
| [[Interferon-alpha|IFN-α]]
| [[Systemic_lupus_erythematosus|SLE]], [[Dermatomyositis|dermatomyositis]], [[Polymyositis|polymyositis]]
|-
| [[Siltuximab|Siltuximab]]
| 
| mab
| chimeric
| [[Interleukin-6|IL-6]]
| cancer
|-
| [[Simtuzumab|Simtuzumab]]
| 
| mab
| humanized
| [[LOXL2|LOXL2]]
| [[Fibrosis|fibrosis]]
|-
| [[Siplizumab|Siplizumab]]
| 
| mab
| humanized
| [[CD2|CD2]]
| psoriasis, [[Graft-versus-host_disease|graft-versus-host disease]] (prevention)
|-
| [[Sirukumab|Sirukumab]]
| 
| mab
| human
| [[Interleukin_6|IL-6]]
| rheumatoid arthritis
|-
| [[Sofituzumab_vedotin|Sofituzumab vedotin]]
| 
| mab
| humanized
| [[CA-125|CA-125]]
| ovarian cancer
|-
| [[Solanezumab|Solanezumab]]
| 
| mab
| humanized
| [[Beta_amyloid|beta amyloid]]
| Alzheimer's disease
|-
| [[Solitomab|Solitomab]]
| 
| BiTE
| mouse
| [[EpCAM|EpCAM]]
| 
|-
| [[Sonepcizumab|Sonepcizumab]]
| 
| 
| humanized
| [[Sphingosine-1-phosphate|sphingosine-1-phosphate]]
| [[Choroidal_neovascularization|choroidal]] and [[Retina|retinal]] [[Neovascularization|neovascularization]]
|-
| [[Sontuzumab|Sontuzumab]]
| 
| mab
| humanized
| episialin
| 
|-
| [[Stamulumab|Stamulumab]]
| 
| mab
| human
| [[Myostatin|myostatin]]
| muscular dystrophy
|-
| [[Sulesomab|Sulesomab]]
| LeukoScan
| Fab'
| mouse
| NCA-90 (granulocyte antigen)
| [[Osteomyelitis|osteomyelitis]] (imaging)
|-
| [[Suvizumab|Suvizumab]]
| 
| mab
| humanized
| [[HIV-1|HIV-1]]
| viral infections
|-
| [[Tabalumab|Tabalumab]]
| 
| mab
| human
| [[B-cell_activating_factor|BAFF]]
| B-cell cancers
|-
| [[Tacatuzumab_tetraxetan|Tacatuzumab tetraxetan]]
| AFP-Cide
| mab
| humanized
| [[Alpha-fetoprotein|alpha-fetoprotein]]
| cancer
|-
| [[Tadocizumab|Tadocizumab]]
| 
| Fab
| humanized
| [[Integrin|integrin]] α<sub>IIb</sub>β<sub>3</sub>
| [[Percutaneous_coronary_intervention|percutaneous coronary intervention]]
|-
| [[Talizumab|Talizumab]]
| 
| mab
| humanized
| [[IgE|IgE]]
| [[Allergic_reaction|allergic reaction]]
|-
| [[Tamtuvetmab|Tamtuvetmab]]
| Tactress
| mab
| veterinary
| [[CD52|CD52]]
| 
|-
| [[Tanezumab|Tanezumab]]
| 
| mab
| humanized
| [[Nerve_growth_factor|NGF]]
| [[Pain|pain]]
|-
| [[Taplitumomab_paptox|Taplitumomab paptox]]
| 
| mab
| mouse
| [[CD19|CD19]]
| cancer{{Citation needed|date=November 2009}}
|-
| [[Tarextumab|Tarextumab]]
| 
| mab
| human
| Notch receptor
| cancer
|-
| [[Tefibazumab|Tefibazumab]]
| Aurexis
| mab
| humanized
| [[Clumping_factor_A|clumping factor A]]
| ''[[Staphylococcus_aureus|Staphylococcus aureus]]'' infection
|-
| [[Telimomab_aritox|Telimomab aritox]]
| 
| Fab
| mouse
| 
| 
|-
| [[Tenatumomab|Tenatumomab]]
| 
| mab
| mouse
| [[Tenascin_C|tenascin C]]
| cancer
|-
| [[Teneliximab|Teneliximab]]
| 
| mab
| chimeric
| [[CD40|CD40]]
| autoimmune diseases and prevention of [[Organ_transplant_rejection|organ transplant rejection]]
|-
| [[Teplizumab|Teplizumab]]
| 
| mab
| humanized
| [[CD3_(immunology)|CD3]]
| [[Diabetes_mellitus_type_1|diabetes mellitus type 1]]
|-
| [[Teprotumumab|Teprotumumab]]
| 
| mab
| human
| [[Insulin-like_growth_factor_1_receptor|IGF-1 receptor (CD221)]]
| hematologic tumors
|-
| [[Tesidolumab|Tesidolumab]]
| 
| mab
| human
| [[Complement_C5|C5]]
| 
|-
| [[Tetulomab|Tetulomab]]
| 
| mab
| humanized
| [[CD37|CD37]]
| cancer {{Cite journal |author1=Jostein Dahle |author2=Ada H. V. Repetto-Llamazares |author3=Camilla S. Mollatt |author4=Katrine B. Melhus |author5=Oyvind S. Bruland |author6=Arne Kolstad |author7=Roy H. Larsen | title = Evaluating antigen targeting and anti-tumor activity of a new anti-CD37 radioimmunoconjugate against non-Hodgkin's lymphoma | journal = [[Anticancer research]] | volume = 33 | issue = 1 | pages = 85–95 | date= January 2013 | pmid = 23267131}}
|-
| [[Tezepelumab|Tezepelumab]]
| 
| mab
| human
| [[Thymic_stromal_lymphopoietin|TSLP]]
| asthma, [[Atopic_dermatitis|atopic dermatitis]]
|-
| [[TGN1412|TGN1412]]
| 
| 
| humanized
| [[CD28|CD28]]
| chronic lymphocytic leukemia, rheumatoid arthritis
|-
| [[Ticilimumab|Ticilimumab]] (= tremelimumab)
| 
| mab
| human
| [[CTLA-4|CTLA-4]]
| cancer
|-
| [[Tildrakizumab|Tildrakizumab]]
| 
| mab
| humanized
| [[Interleukin_23|IL23]]
| immunologically mediated inflammatory disorders
|-
| [[Tigatuzumab|Tigatuzumab]]
| 
| mab
| humanized
| [[TRAIL-R2|TRAIL-R2]]
| cancer
|-
| [[Timolumab|Timolumab]]
| 
| mab
| human
| [[Amine_oxidase_copper_containing_3|AOC3]]
| 
|-
| [[Tisotumab_vedotin|Tisotumab vedotin]]
| mab
| human
| [[Coagulation_factor_III|coagulation factor III]]
| 
|-
| [[TNX-650|TNX-650]]
| 
| 
| humanized
| [[Interleukin_13|IL-13]]
| Hodgkin's lymphoma
|-
| [[Tocilizumab|Tocilizumab]] (= atlizumab)
| Actemra, RoActemra
| mab
| humanized
| [[IL-6_receptor|IL-6 receptor]]
| rheumatoid arthritis
|-
| [[Toralizumab|Toralizumab]]
| 
| mab
| humanized
| [[CD154|CD154]] (CD40L)
| rheumatoid arthritis, lupus nephritis etc.
|-
| [[Tosatoxumab|Tosatoxumab]]
| 
| mab
| human
| ''[[Staphylococcus_aureus|Staphylococcus aureus]]''
| 
|-
| [[Tositumomab|Tositumomab]]
| Bexxar
| 
| mouse
| [[CD20|CD20]]
| [[Follicular_lymphoma|follicular lymphoma]]
|-
| [[Tovetumab|Tovetumab]]
| 
| mab
| human
| [[CD140a|CD140a]]
| cancer
|-
| [[Tralokinumab|Tralokinumab]]
| 
| mab
| human
| [[Interleukin_13|IL-13]]
| asthma etc.
|-
| [[Trastuzumab|Trastuzumab]]
| Herceptin
| mab
| humanized
| [[HER2/neu|HER2/neu]]
| [[Breast_cancer|breast cancer]]
|-
| [[Trastuzumab_emtansine|Trastuzumab emtansine]]
| Kadcyla
| mab
| humanized
| [[HER2/neu|HER2/neu]]
| [[Breast_cancer|breast cancer]]
|-
| [[TRBS07|TRBS07]]>
| Ektomab
| 3funct
| 
| [[GM2_(ganglioside)|GD2 ganglioside]]
| melanoma
|-
| [[Tregalizumab|Tregalizumab]]
| 
| mab
| humanized
| [[CD4|CD4]]
| 
|-
| [[Tremelimumab|Tremelimumab]]
| 
| mab
| human
| [[CTLA-4|CTLA-4]]
| cancer
|-
| [[Trevogrumab|Trevogrumab]]
| 
| mab
| human
| [[Growth_differentiation_factor|growth differentiation factor]] 8
| [[Muscle_atrophy|muscle atrophy]] due to orthopedic disuse and [[Sarcopenia|sarcopenia]]
|-
| [[Tucotuzumab_celmoleukin|Tucotuzumab celmoleukin]]
| 
| mab
| humanized
| [[EpCAM|EpCAM]]
| cancer
|-
| [[Tuvirumab|Tuvirumab]]
| 
| 
| human
| [[Hepatitis_B|hepatitis B]] virus
| chronic hepatitis B
|-
| [[Ublituximab|Ublituximab]]
| 
| mab
| chimeric
| [[MS4A1|MS4A1]]
| cancer
|-
| [[Ulocuplumab|Ulocuplumab]]
| 
| mab
| human
| [[CXCR4|CXCR4 (CD184)]]
| hematologic malignancies
|-
| [[Urelumab|Urelumab]]
| 
| mab
| human
| [[CD137|4-1BB]] (CD137)
| cancer etc.
|-
| [[Urtoxazumab|Urtoxazumab]]
| 
| mab
| humanized
| ''[[Escherichia_coli|Escherichia coli]]''
| diarrhoea caused by ''E. coli''
|-
| [[Ustekinumab|Ustekinumab]]
| Stelara
| mab
| human
| [[Interleukin_12|IL-12]], [[Interleukin_23|IL-23]]
| multiple sclerosis, psoriasis, psoriatic arthritis
|-
| [[Utomilumab|Utomilumab]]
| 
| mab
| human
| [[CD137|4-1BB]] (CD137)
| cancer
|-
| [[Vadastuximab_talirine|Vadastuximab talirine]]
| 
| mab
| chimeric
| [[CD33|CD33]]
| 
|-
| [[Vandortuzumab_vedotin|Vandortuzumab vedotin]]
| 
| mab
| humanized
| [[STEAP1|STEAP1]]
| cancer
|-
| [[Vantictumab|Vantictumab]]
| 
| mab
| human
| [[Frizzled|Frizzled receptor]]
| cancer
|-
| [[Vanucizumab|Vanucizumab]]
| 
| mab
| humanized
| [[Angiopoietin_2|angiopoietin 2]]
| cancer
|-
| [[Vapaliximab|Vapaliximab]]
| 
| mab
| chimeric
| [[AOC3|AOC3]] (VAP-1)
| 
|-
| [[Varlilumab|Varlilumab]]
| 
| mab
| human
| [[CD27|CD27]]
| solid tumors and hematologic malignancies
|-
| [[Vatelizumab|Vatelizumab]]
| 
| mab
| humanized
| [[ITGA2|ITGA2]] (CD49b)
| 
|-
| [[Vedolizumab|Vedolizumab]]
| Entyvio
| mab
| humanized
| [[Integrin|integrin]] α<sub>4</sub>β<sub>7</sub>
| Crohn's disease, [[Ulcerative_colitis|ulcerative colitis]]
|-
| [[Veltuzumab|Veltuzumab]]
| 
| mab
| humanized
| [[CD20|CD20]]
| non-Hodgkin's lymphoma
|-
| [[Vepalimomab|Vepalimomab]]
| 
| mab
| mouse
| [[AOC3|AOC3]] (VAP-1)
| inflammation
|-
| [[Vesencumab|Vesencumab]]
| 
| mab
| human
| [[Neuropilin_1|NRP1]]
| solid malignancies
|-
| [[Visilizumab|Visilizumab]]
| Nuvion
| mab
| humanized
| [[CD3_(immunology)|CD3]]
| Crohn's disease, ulcerative colitis
|-
| [[Vobarilizumab|Vobarilizumab]]
| 
| mab
| humanized
| [[Interleukin_6_receptor|IL6R]]
| inflammatory autoimmune diseases
|-
| [[Volociximab|Volociximab]]
| 
| mab
| chimeric
| [[Integrin|integrin]] α<sub>5</sub>β<sub>1</sub>
| solid tumors
|-
| [[Vorsetuzumab_mafodotin|Vorsetuzumab mafodotin]]
| 
| mab
| humanized
| [[CD70|CD70]]
| cancer
|-
| [[Votumumab|Votumumab]]
| HumaSPECT
| mab
| human
| [[Tumor_antigen|tumor antigen]] CTAA16.88
| colorectal tumors
|-
| [[Xentuzumab|Xentuzumab]]
| 
| mab
| 
| [[Insulin-like_growth_factor_1|IGF1]], [[Insulin-like_growth_factor_2|IGF2]]
| 
|-
| [[Zalutumumab|Zalutumumab]]
| HuMax-EGFr
| mab
| human
| [[Epidermal_growth_factor_receptor|EGFR]]
| [[Squamous_cell_carcinoma_of_the_head_and_neck|squamous cell carcinoma of the head and neck]]
|-
| [[Zanolimumab|Zanolimumab]]
| HuMax-CD4
| mab
| human
| [[CD4|CD4]]
| rheumatoid arthritis, psoriasis, T-cell lymphoma
|-
| [[Zatuximab|Zatuximab]]
| 
| mab
| chimeric
| [[HER1|HER1]]
| cancer
|-
| [[Ziralimumab|Ziralimumab]]
| 
| mab
| human
| [[CD147|CD147]] (basigin)
| 
|-
| [[Zolimomab_aritox|Zolimomab aritox]]
| 
| mab
| mouse
| [[CD5_(protein)|CD5]]
| systemic lupus erythematosus, graft-versus-host disease
|}

{{Reflist|2|refs=
<ref name=WHOList51>{{cite journal | author = [[World Health Organization]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended INN: List 51 | journal = WHO Drug Information | volume = 18 | issue = 1 | year = 2004 | url = http://whqlibdoc.who.int/druginfo/INN_2004_list51.pdf | format=PDF}}</ref>
<ref name=WHOList56>{{cite journal | author = [[World Health Organization]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended INN: List 56 | journal = WHO Drug Information | volume = 20 | issue = 3 | year = 2006 | url = http://whqlibdoc.who.int/druginfo/INN_2006_list56.pdf | format=PDF}}</ref>
<ref name=WHOList66>{{cite journal | author = [[World Health Organization]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 66 | journal = WHO Drug Information | volume = 5 | issue = 4 | year = 1991 | url = http://whqlibdoc.who.int/inn/proposed_lists/prop_INN_list66.pdf | format=PDF}}</ref>
<ref name=WHOList77>{{cite journal | author = [[World Health Organization]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 77 | journal = WHO Drug Information | volume = 11 | issue = 2 | year = 1997 | url = http://whqlibdoc.who.int/inn/proposed_lists/prop_INN_list77.pdf | format=PDF}}</ref>
<ref name=WHOList83>{{cite journal | author = [[World Health Organization]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 83 | journal = WHO Drug Information | volume = 14 | issue = 2 | year = 2000 | url = http://whqlibdoc.who.int/druginfo/DRUG_INFO_14_2_2000_INN-83.pdf | format=PDF}}</ref>
<ref name=WHOList84>{{cite journal | author = [[World Health Organization]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 84 | journal = WHO Drug Information | volume = 14 | issue = 4 | year = 2000 | url = http://whqlibdoc.who.int/druginfo/DRUG_INFO_14_4_2000_INN-84.pdf | format=PDF}}</ref>
<ref name=WHOList85>{{cite journal | author = [[World Health Organization]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 85 | journal = WHO Drug Information | volume = 15 | issue = 2 | year = 2001 | url = http://whqlibdoc.who.int/druginfo/DRUG_INFO_15_2_2001_INN-85.pdf | format=PDF}}</ref>
<ref name=WHOList86>{{cite journal | author = [[World Health Organization]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 86 | journal = WHO Drug Information | volume = 16 | issue = 12 | year = 2002 | url = http://whqlibdoc.who.int/druginfo/16_1_2002_INN86.pdf | format=PDF}}</ref>
<ref name=WHOList87>{{cite journal | author = [[World Health Organization]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 87 | journal = WHO Drug Information | volume = 16 | issue = 2 | year = 2002 | url = http://whqlibdoc.who.int/druginfo/16_2_2002_INN87.pdf | format=PDF}}</ref>
<ref name=WHOList88>{{cite journal | author = [[World Health Organization]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 88 | journal = WHO Drug Information | volume = 17 | issue = 1 | year = 2003 | url = http://whqlibdoc.who.int/druginfo/17_1_2003_INN88.pdf | format=PDF}}</ref>
<ref name=WHOList90>{{cite journal | author = [[World Health Organization]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 90 | journal = WHO Drug Information | volume = 18 | issue = 1 | year = 2004 | url = http://whqlibdoc.who.int/druginfo/18_1_2004_INN90.pdf | format=PDF}}</ref>
<ref name=WHOList91>{{cite journal | author = [[World Health Organization]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 91 | journal = WHO Drug Information | volume = 18 | issue = 2 | year = 2004 | url = http://whqlibdoc.who.int/druginfo/18_2_2004_INN91.pdf | format=PDF}}</ref>
<ref name=WHOList92>{{cite journal | author = [[World Health Organization]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 92 | journal = WHO Drug Information | volume = 18 | issue = 4 | year = 2004 | url = http://whqlibdoc.who.int/druginfo/18_4_2004_INN92.pdf | format=PDF}}</ref>
<ref name=WHOList93>{{cite journal | author = [[World Health Organization]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 93 | journal = WHO Drug Information | volume = 19 | issue = 2 | year = 2008 | url = http://whqlibdoc.who.int/druginfo/19_2_2005_INN93.pdf | format=PDF}}</ref>
<ref name=WHOList94>{{cite journal | author = [[World Health Organization]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 94 | journal = WHO Drug Information | volume = 19 | issue = 4 | year = 2005 | url = http://whqlibdoc.who.int/druginfo/19_4_2005_INN94.pdf | format=PDF}}</ref>
<ref name=WHOList95>{{cite journal | author = [[World Health Organization]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 95 | journal = WHO Drug Information | volume = 20 | issue = 2 | year = 2006 | url = http://whqlibdoc.who.int/druginfo/20_2_2006_INN95.pdf | format=PDF}}</ref>
<ref name=WHOList96>{{cite journal | author = [[World Health Organization]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 96 | journal = WHO Drug Information | volume = 20 | issue = 4 | year = 2006 | url = http://whqlibdoc.who.int/druginfo/20_4_2006_INN96.pdf | format=PDF}}</ref>
<ref name=WHOList97>{{cite journal | author = [[World Health Organization]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 97 | journal = WHO Drug Information | volume = 21 | issue = 2 | year = 2007 | url = http://whqlibdoc.who.int/druginfo/21_2_2007_INN97.pdf | format=PDF}}</ref>
<ref name=WHOList98>{{cite journal | author = [[World Health Organization]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 98 | journal = WHO Drug Information | volume = 21 | issue = 4 | year = 2007 | url = http://www.who.int/medicines/publications/druginformation/innlists/P-List98.pdf | format=PDF}}</ref>
<ref name=WHOList99>{{cite journal | author = [[World Health Organization]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 99 | journal = WHO Drug Information | volume = 22 | issue = 2 | year = 2008 | url = http://www.who.int/entity/medicines/publications/druginformation/issues/INN-PList-No99.pdf | format=PDF}}</ref>
<ref name=WHOList100>{{cite journal | author = [[World Health Organization]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 100 (prepublication copy) | journal = WHO Drug Information | year = 2008 | url = http://www.who.int/entity/medicines/publications/druginformation/innlists/PL100prepubli.pdf | format=PDF}}</ref>
<ref name=WHOList101>{{cite journal | author = [[World Health Organization]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 101 | journal = WHO Drug Information | volume = 23 | issue = 2 | year = 2009 | url = http://whqlibdoc.who.int/druginfo/23_2_2009_INN101.pdf | format=PDF}}</ref>
<ref name=WHOList102>{{cite journal | author = [[World Health Organization]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 102 | journal = WHO Drug Information | volume = 23 | issue = 4 | year = 2009 | url = http://www.who.int/medicines/services/inn/FINAL_PL102.pdf | format=PDF}}</ref>
<ref name=WHOList104>{{cite journal | author = [[World Health Organization]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 104 | journal = WHO Drug Information | volume = 24 | issue = 4 | year = 2010 | url = http://www.who.int/medicines/publications/druginformation/innlists/Final_PL104.pdf | format=PDF}}</ref>
<ref name=WHOList105>{{cite journal | author = [[World Health Organization]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 105 | journal = WHO Drug Information | volume = 25 | issue = 2 | year = 2011 | url = http://www.who.int/medicines/publications/druginformation/innlists/Final_PL105.pdf | format=PDF}}</ref>
<ref name=WHOList103>{{cite journal | author = [[World Health Organization]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 103 | journal = WHO Drug Information | year = 2011 | url = http://www.who.int/medicines/publications/druginformation/INN_PL103.pdf | format=PDF}}</ref>
<ref name=WHOList106>{{cite journal | author = [[World Health Organization]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 106 | journal = WHO Drug Information | volume = 25 | issue = 4 | year = 2011 | url = http://www.who.int/medicines/publications/druginformation/innlists/Final_PL106.pdf | format=PDF}}</ref>
<ref name=WHOList107>{{cite journal | author = [[World Health Organization]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107 | journal = WHO Drug Information | volume = 26 | issue = 2 | year = 2012 | url = http://www.who.int/medicines/publications/druginformation/innlists/Final_PL107.pdf | format=PDF}}</ref>
<ref name=WHOList108>{{cite journal | author = [[World Health Organization]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 108 | journal = WHO Drug Information | volume = 26 | issue = 4 | year = 2012 | url = http://www.who.int/medicines/publications/druginformation/innlists/PL108_Final.pdf | format=PDF}}</ref>
<ref name=WHOList109>{{cite journal | author = [[World Health Organization]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 109 | journal = WHO Drug Information | volume = 27 | issue = 2 | year = 2013 | url = http://www.who.int/medicines/publications/druginformation/innlists/PL109.pdf | format=PDF}}</ref>
<ref name=WHOList110>{{cite journal | author = [[World Health Organization]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 110 | journal = WHO Drug Information | volume = 27 | issue = 4 | year = 2013 | url = http://www.who.int/medicines/publications/druginformation/innlists/PL110.pdf | format=PDF}}</ref>
<ref name=WHOList111>{{cite journal | author = [[World Health Organization]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 111 | journal = WHO Drug Information | volume = 28 | issue = 2 | year = 2014 | url = http://www.who.int/medicines/publications/druginformation/innlists/PL111.pdf | format=PDF}}</ref>
<ref name=WHOList112>{{cite journal | author = [[World Health Organization]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 112 | journal = WHO Drug Information | volume = 28 | issue = 4 | year = 2014 | url = http://www.who.int/medicines/publications/druginformation/innlists/PL112.pdf | format=PDF}}</ref>
<ref name=WHOList113>{{cite journal | author = [[World Health Organization]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 113 | journal = WHO Drug Information | volume = 29 | issue = 2 | year = 2015 | url = http://www.who.int/medicines/publications/druginformation/innlists/PL113.pdf | format=PDF}}</ref>
<ref name=WHOList114>{{cite journal | author = [[World Health Organization]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 114 | journal = WHO Drug Information | volume = 29 | issue = 4 | year = 2015 | url = http://www.who.int/medicines/publications/druginformation/innlists/PL114.pdf | format=PDF}}</ref>
<ref name=WHOList115>{{cite journal | author = [[World Health Organization]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 115 | journal = WHO Drug Information | volume = 30 | issue = 2 | year = 2016 | url = http://www.who.int/medicines/publications/druginformation/innlists/PL115.pdf | format=PDF}}</ref>

<ref name="Brentuximab vedotin">{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Brentuximab vedotin|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/ama1/pub/upload/mm/365/brentuximab-vedotin.pdf}}</ref>
<ref name=Briakinumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Briakinumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/ama1/pub/upload/mm/365/briakinumab.pdf}}</ref>
<ref name="Clivatuzumab tetraxetan">{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Yttrium Y90 clivatuzumab tetraxetan|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/ama1/pub/upload/mm/365/yttrium-Y-90-clivatuzumab-tetraxetan.pdf}}</ref>
<ref name=Fezakinumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Fezakinumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/ama1/pub/upload/mm/365/fezakinumab.pdf}}</ref>
<ref name=Fresolimumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Fresolimumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/ama1/pub/upload/mm/365/fresolimumab.pdf}}</ref>
<ref name=Intetumumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Intetumumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/ama1/pub/upload/mm/365/intetumumab.pdf}}</ref>
<ref name=Lebrikizumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Lebrikizumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/ama1/pub/upload/mm/365/lebrikizumab.pdf}}</ref>
<ref name=Rilotumumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Rilotumumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/ama1/pub/upload/mm/365/rilotumumab.pdf}}</ref>
<ref name=Rontalizumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Rontalizumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/ama1/pub/upload/mm/365/rontalizumab.pdf}}</ref>
<ref name=Sifalimumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Sifalimumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/ama1/pub/upload/mm/365/sifalimumab.pdf}}</ref>
<ref name=Crenezumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Crenezumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/crenezumab.pdf}}</ref>
<ref name=Ficlatuzumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Ficlatuzumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/ficlatuzumab.pdf}}</ref>
<ref name=Amatuximab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Amatuximab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/amatuximab.pdf}}</ref>
<ref name=Brodalumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Brodalumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/brodalumab.pdf}}</ref>
<ref name=Carlumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Carlumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/carlumab.pdf}}</ref>
<ref name=Enavatuzumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Enavatuzumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/enavatuzumab.pdf}}</ref>
<ref name=Enokizumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Enokizumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/enokizumab.pdf}}</ref>
<ref name=Ensituximab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Ensituximab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/ensituximab.pdf}}</ref>
<ref name=Etrolizumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Etrolizumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/etrolizumab.pdf}}</ref>
<ref name=Fulranumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Fulranumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/fulranumab.pdf}}</ref>
<ref name=Gevokizumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Gevokizumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/gevokizumab.pdf}}</ref>
<ref name=Icrucumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Icrucumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/icrucumab.pdf}}</ref>
<ref name=Ixekizumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Ixekizumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/ixekizumab.pdf}}</ref>
<ref name=Mavrilimumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Mavrilimumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/mavrilimumab.pdf}}</ref>
<ref name=Mogamulizumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Mogamulizumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/mogamulizumab.pdf}}</ref>
<ref name="Moxetumomab pasudotox">{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Moxetumomab Pasudotox|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/moxetumomab-pasudotox.pdf}}</ref>
<ref name=Narnatumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Narnatumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/narnatumab.pdf}}</ref>
<ref name=Onartuzumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Onartuzumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/onartuzumab.pdf}}</ref>
<ref name=Oxelumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Oxelumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/oxelumab.pdf}}</ref>
<ref name=Ozoralizumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Ozoralizumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/ozoralizumab.pdf}}</ref>
<ref name=Ponezumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Ponezumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/ponezumab.pdf}}</ref>
<ref name=Secukinumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Secukinumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/secukinumab.pdf}}</ref>
<ref name=Sirukumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Sirukumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/sirukumab.pdf}}</ref>
<ref name=Tabalumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Tabalumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/tabalumab.pdf}}</ref>
<ref name=Urelumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Urelumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/urelumab.pdf}}</ref>
<ref name=Dalotuzumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Dalotuzumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/dalotuzumab.pdf}}</ref>
<ref name=Drozitumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Drozitumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/drozitumab.pdf}}</ref>
<ref name=Samalizumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Samalizumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/samalizumab.pdf}}</ref>
<ref name=Teprotumumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Teprotumumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/teprotumumab.pdf}}</ref>
<ref name=Tralokinumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Tralokinumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/tralokinumab.pdf}}</ref>
<ref name=Ganitumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Ganitumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/ganitumab.pdf}}</ref>
<ref name=Flanvotumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Flanvotumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/flanvotumab.pdf}}</ref>
<ref name=Romosozumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Romosozumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/romosozumab.pdf}}</ref>
<ref name=Sarilumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Sarilumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/ama1/pub/upload/mm/365/sarilumab.pdf}}</ref>
<ref name=Clazakizumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Clazakizumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/clazakizumab.pdf}}</ref>
<ref name=Nivolumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Nivolumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/nivolumab.pdf}}</ref>
<ref name=Placulumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Placulumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/placulumab.pdf}}</ref>
<ref name=Ocaratuzumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Ocaratuzumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/ocaratuzumab.pdf}}</ref>
<ref name=Alirocumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Alirocumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/alirocumab.pdf}}</ref>
<ref name=Demcizumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Demcizumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/demcizumab.pdf}}</ref>
<ref name=Fasinumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Fasinumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/fasinumab.pdf}}</ref>
<ref name="Vorsetuzumab mafodotin">{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Vorsetuzumab Mafodotin|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/vorsetuzumab_mafodotin.pdf}}</ref>
<ref name=Actoxumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Actoxumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/actoxumab.pdf}}</ref>
<ref name=Bezlotoxumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Bezlotoxumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/bezlotoxumab.pdf}}</ref>
<ref name=Dupilumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Dupilumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/dupilumab.pdf}}</ref>
<ref name=Nesvacumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Nesvacumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/nesvacumab.pdf}}</ref>
<ref name=Ozanezumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Ozanezumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/ozanezumab.pdf}}</ref>
<ref name=Pidilizumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Pidilizumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/pidilizumab.pdf}}</ref>
<ref name=Tildrakizumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Tildrakizumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/tildrakizumab.pdf}}</ref>
<ref name=Dusigitumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Dusigitumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/dusigitumab.pdf}}</ref>
<ref name=Eldelumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Eldelumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/eldelumab.pdf}}</ref>
<ref name=Guselkumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Guselkumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/guselkumab.pdf}}</ref>
<ref name=Margetuximab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Margetuximab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/margetuximab.pdf}}</ref>
<ref name=Tovetumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Tovetumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/tovetumab.pdf}}</ref>
<ref name=Vantictumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Vantictumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/vantictumab.pdf}}</ref>
<ref name=Anifrolumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Anifrolumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/anifrolumab.pdf}}</ref>
<ref name=Ontuxizumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Ontuxizumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/ontuxizumab.pdf}}</ref>
<ref name=Aducanumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Aducanumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/aducanumab.pdf}}</ref>
<ref name=Otlertuzumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Otlertuzumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/otlertuzumab.pdf}}</ref>
<ref name=Abrilumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Abrilumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/x-pub/abrilumab.pdf}}</ref>
<ref name=Bimagrumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Bimagrumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/x-pub/bimagrumab.pdf}}</ref>
<ref name=Dinutuximab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Dinutuximab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/x-pub/dinutuximab.pdf}}</ref>
<ref name=Diridavumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Diridavumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/x-pub/diridavumab.pdf}}</ref>
<ref name=Durvalumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Durvalumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/x-pub/durvalumab.pdf}}</ref>
<ref name=Emibetuzumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Emibetuzumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/x-pub/emibetuzumab.pdf}}</ref>
<ref name="Enfortumab vedotin">{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Enfortumab Vedotin|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/x-pub/enfortumab-vedotin.pdf}}</ref>
<ref name=Evinacumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Evinacumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/x-pub/evinacumab.pdf}}</ref>
<ref name=Fletikumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Fletikumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/x-pub/fletikumab.pdf}}</ref>
<ref name="Lifastuzumab vedotin">{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Lifastuzumab Vedotin|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/x-pub/lifastuzumab-vedotin.pdf}}</ref>
<ref name=Ligelizumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Ligelizumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/x-pub/ligelizumab.pdf}}</ref>
<ref name="Lulizumab pegol">{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Lulizumab Pegol|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/x-pub/lulizumab-pegol.pdf}}</ref>
<ref name=Obiltoxaximab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Obiltoxaximab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/x-pub/obiltoxaximab.pdf}}</ref>
<ref name=Pembrolizumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Pembrolizumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/x-pub/pembrolizumab.pdf}}</ref>
<ref name="Polatuzumab vedotin">{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Polatuzumab Vedotin|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/x-pub/polatuzumab-vedotin.pdf}}</ref>
<ref name="Sofituzumab vedotin">{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Sofituzumab Vedotin|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/x-pub/sofituzumab-vedotin.pdf}}</ref>
<ref name=Tarextumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Tarextumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/x-pub/tarextumab.pdf}}</ref>
<ref name=Varlilumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Varlilumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/x-pub/varlilumab.pdf}}</ref>
<ref name=Ulocuplumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Ulocuplumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/x-pub/ulocuplumab.pdf}}</ref>
<ref name=Ralpancizumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Ralpancizumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/x-pub/ralpancizumab.pdf}}</ref>
<ref name=Bococizumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Bococizumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/x-pub/bococizumab.pdf}}</ref>
<ref name=Ascrinvacumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Ascrinvacumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/x-pub/ascrinvacumab.pdf}}</ref>
<ref name=Enoblituzumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Enoblituzumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/x-pub/enoblituzumab.pdf}}</ref>
<ref name="Derlotuximab biotin">{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Iodine I 131 Derlotuximab biotin|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/x-pub/iodine-i-131-derlotuximab-biotin.pdf}}</ref>
<ref name=Isatuximab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Isatuximab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/x-pub/isatuximab.pdf}}</ref>
<ref name=Refanezumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Refanezumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/x-pub/refanezumab.pdf}}</ref>
<ref name=Rinucumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Rinucumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/x-pub/rinucumab.pdf}}</ref>
<ref name=Opicinumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Opicinumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/x-pub/opicinumab.pdf}}</ref>
<ref name="Mirvetuximab soravtansine">{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Mirvetuximab Sorevtansine|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/x-pub/mirvetuximab-soravtansine.pdf}}</ref>
<ref name="Sacituzumab govitecan">{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Sacituzumab Govitecan|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/x-pub/sacituzumab-govitecan.pdf}}</ref>
<ref name=Trevogrumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Trevogrumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/x-pub/trevogrumab.pdf}}</ref>

<ref name=NCT00883896>{{ClinicalTrialsGov|NCT00883896|Study to Evaluate the Safety and Efficacy of ILV-094 in Subjects With Rheumatoid Arthritis}}</ref>
<ref name=NCT00563524>{{ClinicalTrialsGov|NCT00563524|Study Evaluating the Safety and Tolerability of ILV-094 in Subjects With Psoriasis}}</ref>
<ref name=NCT00537381>{{ClinicalTrialsGov|NCT00537381|A Study of the Safety and Effectiveness of CNTO 95 in Patients With Metastatic Hormone Refractory Prostate Cancer}}</ref>
<ref name=NCT00246012>{{ClinicalTrialsGov|NCT00246012|A Study of the Safety and Efficacy CNTO 95 in Subjects With Advanced Melanoma}}</ref>

<ref name="ALD518">{{cite news|url=http://www.genengnews.com/news/bnitem.aspx?name=68068627&source=genwire|title=BMS Shells Out $85M Up Front for Alder’s Mid-Stage Rheumatoid Arthritis Antibody|date=10 November 2009|publisher=Genetic Engineering & Biotechnology News}}</ref>
<ref name="IMA-638">{{cite web|url=http://www.wyeth.com/research/projects |title=Wyeth.com {{!}} Complete Project Listing |year=2008 |publisher=[[Wyeth]] |accessdate=November 19, 2008 |archiveurl=https://web.archive.org/web/20080612044330/http://www.wyeth.com/research/projects |archivedate=June 12, 2008 |deadurl=yes |df= }}</ref>
<ref name="Glembatumumab">[[National Cancer Institute|NCI]] Drug Dictionary: [http://www.cancer.gov/drugdictionary/?CdrID=599456 Glemtumumab vedotin]</ref>
<ref name=Ch1418>{{cite web|url=https://www.sec.gov/Archives/edgar/data/1082554/000104746911001229/a2202121z10-k.htm#da77001_item_1._business|title=United Therapeutics 10-K report|accessdate=5 November 2011}}</ref>
}}